Merck & Co. (MRK) Stock Price

Live Merck & Co. Stock Price, Historical MRK Stock Price Chart

24H Range
 
 
 
52W Range
 
 
 
Last Price $ 147.76
Open $ 147.31
Previous Close $ 146.95
Volume $ 935.08M
ATH $ 156.92 (-5.84%)
ExchangeNYSE
P/E Ratio (TTM) 47.36
EPS (TTM) $ 3.12
Annual Dividend (Yield) $ 3.40 (2.30%)
Market Cap $ 364.27B
Merck & Co. Performance
Prev. Close 7 Days 1 Month 3 Months 6 Months 1 Year YTD 5 Year Max
0.55% -0.64% 1.77% 8.67% 31.27% 59.02% 38.81% 76.56% 10.09K%

About Merck & Co.

Statistics

The Merck & Co. stock price is currently $ 147.76 with a total market cap valuation of $ 364.27B (2.47B shares outstanding). The Merck & Co. is trading on NYSE under the ticker sign MRK. Merck & Co. price is up 0.55% in the past 24 hours. The Merck & Co. stock price prediction is currently bullish. The Merck & Co. trailing twelve month dividend rate is $ 3.40 per share with dividend yield of 2.30%.

You can buy Merck & Co. (MRK) stock on eToro. For more information check our how to buy Merck & Co. (MRK) stock guide.

Description

Company Profile

Brokers

Plus500
Trade the world's most popular markets: CFDs on Forex, Cryptocurrencies, Shares...

Trading with leverage comes with a high risk and may not be suitable for everyone. You should consider whether you can afford to take the high risk of losing your money. 80% of retail CFD accounts lose money.

News

Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
What Merck KGaA (MRK) Said on Its Q3 Earnings Call
Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year
FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
MRK's 2027 Outlook Challenging, Long-Term Prospects Promising
Two 70-Year-Olds Will Start the Same $12,272 Keytruda Qlex Cancer Injections. One With Medigap Plan G Will Owe $0 in Coinsurance After the Part B Deductible, While the Other Will Owe 20% With No Annual Cap
Merck & Co., Inc. $MRK Stock Purchased by Asset One Wealth Management LLC

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

MRK
Merck & Co.
$ 147.76
-0.64%   Last 7D
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Updated 20 hours ago